Navigation Links
SomaGenics Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation NIH Grants
Date:11/12/2012

SANTA CRUZ, Calif., Nov. 12, 2012 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, has been awarded US Patent No. 8,283,460 for key aspects of the company's sshRNA therapeutic platform.  sshRNAs are small synthetic stem-loop (or hairpin) RNAs that the company's researchers have shown to be highly potent in knocking down target RNAs through an RNA interference (RNAi) mechanism.  SomaGenics' lead therapeutic program targets hepatitis C, and a number of sshRNAs directed at the hepatitis C virus are covered by the new patent.  'This patent, following on the award of US Patent 7,902,351 in 2011, represents another significant milestone in securing comprehensive patent protection for our sshRNA technology," commented SomaGenics CEO Brian Johnston.

SomaGenics also announced the receipt of two Small Business Innovation Grants from the National Institutes of Health totaling $647,000.  One, from the National Institute of General Medical Sciences, is entitled Accelerating Wound Healing Using RNAi and aims to speed healing of the hard-to-heal wounds that can particularly plague diabetics.  Dr. Sumedha Jayasena, VP of Therapeutic Development at SomaGenics, is principal investigator.

A second grant, awarded by the National Cancer Institute, is entitled A Novel Method for Quantitation of Fragmented mRNAs.  Its goal is to develop a new approach to analyzing gene expression from formalin-fixed, paraffin-embedded (FFPE) tissue specimens. Large repositories of FFPE specimens, each with pathologist interpretation and clinical records, are available at many medical institutions.  The ability to determine gene expression profiles for each specimen could make these archives a rich resource for discovering mRNA biomarkers of disease. Although RT-qPCR is the preferred method for quantitative analysis of gene expression, its sensitivity and robustness are significantly reduced with FFPE samples due to the degradation of mRNAs that occurs during specimen preparation and storage. SomaGenics' mR-FQ RT-qPCR approach should overcome these problems because, unlike standard PCR methods, it is unaffected by fragmentation; indeed, it explicitly makes use of it. The principal investigator for this grant is Dr. Sergei Kazakov, VP of Discovery Research at SomaGenics.

The new awards bring SomaGenics' total grant funding to well over $18 million and allow the company to develop new applications for its technologies.

Contact:

Dr. Brian Johnston
CEO, SomaGenics, Inc.
www.somagenics.com
bjohnston@somagenics.com
831-426-7700 x12

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE SomaGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
2. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
3. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
4. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
5. Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
7. Boston Childrens Hospital announces international genomics competition winner
8. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
9. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
10. AMRI Announces Third Quarter 2012 Results
11. Egenix, Inc. Announces New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
Breaking Biology Technology:
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
Breaking Biology News(10 mins):